Business Description
Ascletis Pharma Inc
ISIN : KYG0520K1094
Share Class Description:
FRA:2VJ: Ordinary SharesTotal Employee Number:
202Compare
Compare
Traded in other countries / regions
01672.Hong KongASCLF.USA2VJ.Germany IPO Date
2018-08-08Description
Ascletis Pharma Inc is an investment holding company. The company is a fully integrated biotechnology company focused on the development and commercialization of potential therapeutics to treat metabolic diseases. Along with its subsidiaries, it is engaged in the research, development, production, marketing, and sale of pharmaceutical products. The company uses its Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP) technologies and Peptide Oral Transport ENhancement Technology (POTENT) to develop multiple drug candidates in-house, including both small molecules and peptides. The drug candidates of the company in the pipeline in their different stages of development such as ASC30, ASC47, ASC39, ASC36i, ASC35, ASC50, and among others.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 606.97 | |||||
Equity-to-Asset | 0.93 | |||||
Debt-to-EBITDA | -0.01 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | 43.76 | |||||
Beneish M-Score | -1.52 | |||||
WACC vs ROIC | ||||||
Growth Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -67.1 | |||||
3-Year EBITDA Growth Rate | -9.9 | |||||
3-Year EPS without NRI Growth Rate | -17.2 | |||||
3-Year FCF Growth Rate | -28.8 | |||||
3-Year Book Growth Rate | -6 |
Momentum Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 57.45 | |||||
9-Day RSI | 52.93 | |||||
14-Day RSI | 51.08 | |||||
3-1 Month Momentum % | -18.02 | |||||
6-1 Month Momentum % | -44.17 | |||||
12-1 Month Momentum % | -38.93 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 12.92 | |||||
Quick Ratio | 12.91 | |||||
Cash Ratio | 12.76 | |||||
Days Inventory | 1771.61 | |||||
Days Sales Outstanding | 99.33 | |||||
Days Payable | 3754.34 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 3.2 | |||||
Shareholder Yield % | -3.55 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 42.93 | |||||
Operating Margin % | -71757.55 | |||||
Net Margin % | -64070.46 | |||||
EBITDA Margin % | -63989.87 | |||||
FCF Margin % | -62260.87 | |||||
OCF Margin % | -62167.83 | |||||
ROE % | -29.54 | |||||
ROA % | -27.54 | |||||
ROIC % | -273.37 | |||||
3-Year ROIIC % | -141.23 | |||||
ROC (Joel Greenblatt) % | -1291.2 | |||||
ROCE % | -29.45 | |||||
Moat Score | 4 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 10330 | |||||
PB Ratio | 4.17 | |||||
Price-to-Tangible-Book | 4.19 | |||||
EV-to-EBIT | -11.74 | |||||
EV-to-EBITDA | -11.74 | |||||
EV-to-Revenue | 7515.08 | |||||
EV-to-FCF | -12.11 | |||||
Price-to-GF-Value | 109 | |||||
| Price-to-Net-Current-Asset-Value | 4.54 | |||||
| Price-to-Net-Cash | 4.54 | |||||
Earnings Yield (Greenblatt) % | -8.52 | |||||
FCF Yield % | -5.98 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ascletis Pharma Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.115 | ||
| EPS (TTM) (€) | -0.073 | ||
| Beta | -0.3534 | ||
| 3-Year Sharpe Ratio | 0.83 | ||
| 3-Year Sortino Ratio | 1.97 | ||
| Volatility % | 91.06 | ||
| 14-Day RSI | 51.08 | ||
| 14-Day ATR (€) | 0.039295 | ||
| 20-Day SMA (€) | 1.1015 | ||
| 12-1 Month Momentum % | -38.93 | ||
| 52-Week Range (€) | 0.91 - 2.06 | ||
| Shares Outstanding (Mil) | 1,049.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ascletis Pharma Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ascletis Pharma Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Second quarter earnings conference call for 2026 | 2026-09-01 10:00 | 1.03 (-0.96%) | ||
| Second quarter earnings results for 2026 | 2026-09-01 | 1.03 (-0.96%) | ||
| General meeting for 2026 | 2026-06-29 09:00 | 1.05 (-1.87%) | ||
| Annual report for 2025 | 2026-04-29 | 1.83 (+2.23%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-31 | 1.83 (+0.00%) | ||
| Second quarter earnings conference call for 2025 | 2025-08-18 | 1.89 (+0.00%) | ||
| Second quarter earnings results for 2025 | 2025-08-15 | 1.67 (+0.00%) | ||
| General meeting for 2025 | 2025-05-22 | 0.78 (-2.50%) | ||
| Fourth quarter earnings results for 2024 | 2025-03-26 | 1.00 (-2.91%) |
Show
Entries
Ascletis Pharma Inc Frequently Asked Questions
What is Ascletis Pharma Inc(FRA:2VJ)'s stock price today?
The current price of FRA:2VJ is €1.09. The 52 week high of FRA:2VJ is €2.06 and 52 week low is €0.91.
When is next earnings date of Ascletis Pharma Inc(FRA:2VJ)?
The next earnings date of Ascletis Pharma Inc(FRA:2VJ) is 2027-03-31 Est..
Does Ascletis Pharma Inc(FRA:2VJ) pay dividends? If so, how much?
Ascletis Pharma Inc(FRA:2VJ) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on Ascletis Pharma Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers